source
- AstraZeneca’s ATTR-CM Silencer Trial Fails to Show Benefit Over Existing Stabilizer TherapyAstraZeneca announced that its Phase 3 trial of a silencer drug for transthyretin amyloid cardiomyopathy (ATTR-CM) did not meet its primary endpoints. The study showed no additional clinical benefi…
- AstraZeneca and Ionis gene silencer Wainua fails trial after patients also took Pfizer heart drugAt the ESC Congress in Munich, a high‑profile trial of the gene‑silencing therapy Wainua, developed by AstraZeneca and Ionis, was reported to have failed. The failure was linked to participants co…